Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany
· Delayed Price · Currency is EUR | Market Cap | 100.04B |
| Revenue (ttm) | 10.27B |
| Net Income (ttm) | -914.93M |
| Shares Out | n/a |
| EPS (ttm) | -3.55 |
| PE Ratio | n/a |
| Forward PE | 23.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Average Volume | 245 |
| Open | 387.75 |
| Previous Close | 392.95 |
| Day's Range | 387.75 - 389.15 |
| 52-Week Range | 362.70 - 489.20 |
| Beta | 0.46 |
| RSI | 42.78 |
| Earnings Date | May 5, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver...
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceutica...
Vertex Pharma announces new share buybacks worth up to $4B
Vertex to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor...
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
The Investment Committee give you their top names to watch for the second half.
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
The Investment Committee give you their top names to watch for the second half.
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss
Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 2025 results. Read more here.
SA analyst upgrades: TSLA, MSFT, AMD, PLTR, VRTX, ONON, CB
Explore recent stock upgrades by Seeking Alpha: TSLA, MSFT, AMD & more! Discover insights and investment strategies for outperforming the market.
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain manage...
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Vertex posted Q1 EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U.S. ... Full story available on Benzinga.com
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Heres Why.
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following ...
Vertex Pharmaceuticals Stock Sinks as Costs Soar
Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.
Tech faces turbulence as energy stocks surge: A detailed market analysis
Sector Overview The tech sector is navigating choppy waters today, with major players showing mixed results. Microsoft (MSFT) slipped slightly at -0.34%, while Nvidia (NVDA), a significant semiconduct...
Why Vertex Pharmaceuticals Stock Is Sinking Today
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Needham c...
Stocks making the biggest moves premarket: Palantir Technologies, Ford Motor, Vertex Pharmaceuticals, DoorDash and more
These are some of the stocks posting the largest moves in premarket trading.
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd . (NASDAQ: ICHR) fell sharply in today's pre-market trading after th...
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday.
This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...